Nils Wilking

Efficacy of HER2-targeted therapy in early breast cancer 2008–2020 in Sweden in the real-world setting

Abstract Large-scale real-world evidence on outcomes in HER2-positive (HER2 +) early breast cancer (EBC) remains limited. We investigated overall survival (OS) and its prognostic factors in patients with HER2+ EBC. We here analyzed data from 4,638 patients with HER2 + EBC diagnos...